The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells
In Vivo · 2026
DOI: 10.21873/invivo.14420 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2026. Verfasst von Jinsoo Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Breast Neoplasms, Carbon-Sulfur Lyases, Phosphoinositide-3 Kinase Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AntiCancer Inc., San Diego, CA, U.S.A.
- Department of Surgery, University of California, San Diego, CA, U.S.A.
- Department of Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- AntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.
Zitieren
APA
Kim, J., Han, Q., Li, S., Miyashi, Y., Ishiguro, T., Bouvet, M., & Hoffman, R. M. (2026). The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells. In Vivo. https://doi.org/10.21873/invivo.14420
Vancouver
Kim J, Han Q, Li S, Miyashi Y, Ishiguro T, Bouvet M, et al. The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells. In Vivo. 2026. doi:10.21873/invivo.14420
BibTeX
@article{Kim2026,
author = {Kim, Jinsoo and Han, Qinghong and Li, Shukuan and Miyashi, Yuta and Ishiguro, Tomoyuki and Bouvet, Michael and Hoffman, Robert M},
title = {The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14420}
}
EUVIMED